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Abstract
Background: To determine the association between extreme values of first trimester markers and adverse pregnancy outcomes.
Methods: A retrospective cohort study of 916 women who underwent first-trimester combined screening during 2015 was performed. Extreme
values of NT, pregnancy-associated plasma protein-A (PAPP-A) and free b-hCG, and their association with adverse pregnancy outcomes were analyzed.
Results: Low PAPP-A (510th percentile) was associated with an increased risk for preeclampsia (adjusted odds ratio (AOR) 4.13), fetal growth
restriction (AOR 3.94) and abruptio placentae (AOR 52.63). Abnormally low or high free b-hCG, high PAPP-A or increased NTwas not associated with an
increased risk for adverse outcomes.
Discussion: PAPP-A510th percentile could be associated with an increased risk for adverse outcomes. However, the majority of patients with these
events do not have abnormal PAPP-A and few patients with PAPP-A510th percentile will have an adverse outcome.
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Introduction
Maternal serum markers obtained in ﬁrst trimester Down syndrome
screening include pregnancy-associated plasma protein-A (PAPP-A)
and free beta-human chorionic gonadotropin (free b-hCG). The com-
bined test (sonographic measurement of fetal nuchal translucency (NT)
and maternal serum markers) detects 85 percent of Down syndrome
fetuses at a ﬁve percent false positive rate.1,2 Although the primary goal
of this screening is to detect these disorders, recent studies describe the
association between individual extreme levels of Down syndrome
screening markers and adverse pregnancy outcomes, including preterm
birth, fetal growth disorders, hypertensive disorders and spontaneous
abortion.3–15 The aim of this study was to determine the association
and predictive ability of extreme values of PAPP-A, free b-hCG and
NT with adverse pregnancy outcomes.
Methods
A retrospective cohort study was performed including women with a
singleton gestation who underwent ﬁrst-trimester screening for aneu-
ploidy between 11 weeks 0 days and 13 weeks 6 days of gestation (fetal
crown-rump length between 45 and 84mm) at Alto Minho Local
Healthcare Unit, Viana do Castelo, Portugal, during 2015. Women
who had a fetal demise before 22 weeks of gestation or whose fetuses
were conﬁrmed to have chromosome abnormalities or other malfor-
mation were excluded. Likewise, records with incomplete outcome
data were not included. The three ﬁrst-trimester markers PAPP-A
level, free b-hCG and NT were evaluated. Values for the two serum
markers were obtained by a certiﬁcated laboratory and NT measure-
ments were obtained by a maternal fetal medicine specialist with Fetal
Medicine Foundation certiﬁcation. Information on maternal sociode-
mographics, medical and obstetrical history, gestational age at exam-
ination, pregnancy course and delivery outcome were collected. In a
primary analysis, extreme values of NT (2.5mm), PAPP-A (51st, 5th
and 10th percentiles,490th, 95th and 99th percentiles) and free b-hCG
(51st, 5th and 10th percentiles,490th, 95th and 99th percentiles) were
evaluated, as well as their association with adverse pregnancy out-
comes. Percentiles were deﬁned using FASTER study6 (Table 1). In
a second analysis, women with a PAPP-A510th percentile multiples of
median (MoM) were compared to those with a PAPP-A 10th per-
centile. In the ﬁnal adjusted models, some variables were considered to
be confounders for preeclampsia, namely, maternal age, parity and
chronic hypertension. Gestational hypertension, chronic hypertension,
pregestational diabetes and preeclampsia were considered for fetal
growth restriction; and maternal age, parity, gestational hypertension
and chronic hypertension, gestational age at delivery and infant sex
were considered for abruptio placentae. Performance characteristics,
which included the adjusted odds ratios (AOR) and 95% conﬁdence
interval (CI), sensitivity, speciﬁcity and positive predictive value (PPV)
and negative predictive value (NPV) for PAPP-A were estimated for
each outcome.
Outcome measurements
The outcome measurements examined included preterm birth, gesta-
tional hypertension, preeclampsia, third trimester fetal growth restric-
tion, low birth weight, preterm premature rupture of membranes
(PPROM), abruptio placentae, gestational diabetes, macrosomia and
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oligohydramnios. Preterm birth was deﬁned, according to World
Health Organization, as a delivery occurring before 37 weeks of preg-
nancy. Gestational hypertension was deﬁned as new onset of hyper-
tension (systolic blood pressure 140mmHg and/or diastolic blood
pressure 90mmHg) at 20 weeks of gestation, in the absence of
proteinuria or new signs of end-organ dysfunction. The blood pressure
readings were documented on at least two occasions at least four hours
apart, according to the American College of Obstetricians and
Gynecologists (ACOG). Preeclampsia was deﬁned as new onset of
hypertension and either proteinuria or end-organ dysfunction after
20 weeks of gestation. Criteria for diagnosis were: systolic blood
pressure 140mmHg or diastolic blood pressure 90mmHg, and pro-
teinuria 0.3 g in a 24 h urine specimen or protein:creatinine ratio
0.3, or signs of end-organ dysfunction (platelet count5100,000/mL,
serum creatinine41.1mg/dL or doubling of the serum creatinine, ele-
vated serum transaminases to twice normal concentration), according
to ACOG. Third trimester fetal growth restriction was deﬁned as a
fetus whose estimated weight was below the 10th percentile for gesta-
tional age, calculated by ASTRAIA software, after 27 weeks 0 days of
gestation. Low birth weight was deﬁned as a birth weight of a liveborn
of less than 2500 g, regardless of gestational age, according to ACOG.
PPROM was deﬁned as the rupture of the membranes before the onset
of labor until 37 weeks of gestation. Abruptio placentae was deﬁned as
bleeding at the decidual-placental interface that causes partial or com-
plete placental detachment prior to delivery of the fetus. The diagnosis
was primarily clinical and conﬁrmed by ultrasound or intra-operatory
visualization of placental detachment. Gestational diabetes was diag-
nosed if fasting glucose level 92 and5126mg/dL at ﬁrst trimester or
at least one value of plasma glucose concentration 92, 180 and
153mg/dL (for fasting, 1- and 2-h post glucose load glucose values,
respectively), after performing a 75 g oral glucose tolerance test at
24–28 weeks of gestation.16Macrosomia was deﬁned as a birth
weight greater than 4500 g. Oligohydramnios was deﬁned as amniotic
ﬂuid index 5 cm or the absence of a single deepest pocket
52 1 cm2.17
Statistical analysis
Continuous variables were described using median and interquartile
ranges and categorical variables using frequencies. Continuous vari-
ables were compared between groups using Mann–Whitney U test and
dichotomous variables using Fisher’s exact test or Chi-square test, as
appropriate. In the ﬁnal phase, logistic regression analysis was per-
formed to evaluate possible confounding or adjustment factors. OR
and 95% CI were calculated. Statistical analyses were performed with
the SPSS package (SPSS Inc., Chicago IL, version 23). Statistical sig-
niﬁcance was deﬁned as p value50.05.
Results
The study population included all women whom PAPP-A level, free
b-hCG and NT were available (N ¼ 1025). One hundred and nine
(10.63%) women were excluded (Figure 1). The patients included in
this study did not diﬀer signiﬁcantly in sociodemographics from those
who were excluded and population’s characteristics, with relevant
patient history, demographic data and obstetric history are summar-
ized in Table 2.
Among the 916 women, 31 (3.4%) had a preterm birth, 21 (2.3%)
developed gestational hypertension, 12 (1.3%) had preeclampsia, 27
(2.9%) had third trimester fetal growth restriction, 43 (4.7%) had a
low birth weight newborn, 10 (1.1%) had a PPROM, 3 (0.3%) had
Figure 1. Flow chart of study population selection.
PPROM: preterm premature rupture of membranes.
Table 1. Relationship between analytic per-
centiles and multiples of the median (FASTER
trial).
Percentile
PAPP-A
(MoM)
Free b-hCG
(MoM)
1st 0:28 0.24
5th 0:42 0.35
10th 0:52 0.44
90th 2:04 2.94
95th 2:51 3.91
99th 3:73 6.56
MoM: multiples of median; b-hCG: free beta-human
chorionic gonadotropin; PAPP-A: pregnancy-asso-
ciated plasma protein-A.
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abruptio placentae, 125 (13.6%) developed gestational diabetes,
3 (0.3%) had a macrosomic newborn and 14 (1.5%) had oligohy-
dramnios. Only low PAPP-A level was associated with adverse preg-
nancy outcome. There was a statistically signiﬁcant association
between: PAPP-A510th percentile and preeclampsia (adjusted odds
ratio, AOR, 4.13, CI 1.15–4.80); low PAPP-A (51st, 5th and 10th
percentiles) and third trimester fetal growth restriction (AOR 8.62,
4.76, 3.94, respectively); and PAPP-A510th percentile and abruptio
placentae (AOR 52.63, 1.41–100.0) (Tables 2 and 3). For fetal growth
restriction, there was an increased risk for an adverse outcome as the
PAPP-A level became increasingly extreme, from 10th to 1st percent-
ile. Because low PAPP-A (510th percentile) level had the most sig-
niﬁcant associations with adverse pregnancy outcomes, the
characteristics of two groups were compared (Table 2) and the sensi-
tivity, speciﬁcity and positive and NPVs for PAPP-A50.52 MoM was
calculated (Table 3). Concerning PAPP-A 510th percentile, it was
observed for preeclampsia 33.3% sensitivity with 3.88% PPV; for
third trimester fetal growth restriction 33.3% sensitivity with 8.74%
PPV; and for abruptio placentae 66.67% sensitivity, with 1.94% PPV
(Table 4).
Discussion
The aim of this study was to analyze the association of extreme values
of PAPP-A, free b-hCG and NT with adverse pregnancy outcomes.
Table 2. Patients’ characteristics by PAPP-A510th percentile MoM versus PAPP-A 10th percentile MoM.
All
(N¼ 916)
PAPP-A510th
percentile
(N¼ 103)
PAPP-A 10th
percentile
(N¼ 813) p-Value
Maternal age (years) 31 (28–35) 31 (29–34) 31 (28–35) 0:77
Parity 1 (0–1) 1 (0–1) 1 (0–1) 0:55
Previous preterm birth 9 (1%) 2 (1.9%) 7 (0.9%) 0:27
Pregestational diabetes 8 (0.9%) 3 (2.9%) 5 (0.6%) 0:05
Chronic hypertension 20 (2.2%) 3 (2.9%) 7 (2.1%) 0:48
Ultrasound marker
NT 2.5 mm
70 (7.6%) 2 (1.9%) 68 (8.4%) 0:02
Serum marker
Free b-hCG (MoM)
0.889 (0.608–1.389) 0.68 (0.49–0.966) 0.919 (0.629–1.414) 0:000
First trimester combined risk41:300 26 (2.8%) 9 (8.7%) 17 (2.1%) 0:001
Amniocentesis 30 (3.3%) 6 (5.8%) 24 (3.0%) 0:14
Delivery
Duration of pregnancy (weeks) 39 (38–40) 39 (38–40) 39 (39–40) 0:04
Spontaneous labor 582 (63.5%) 64 (62.1%) 518 (63.7%) 0:75
No operative delivery 516 (56.3%) 39 (37.9%) 456 (56.1%) 0:75
Male sex 445 (48.6%) 64 (62.1%) 407 (50.1%) 0:02
Birth weight (g) 3282.5 (2980–3560) 3120 (2907.5–3527.5) 3300 (2990–3571) 0:02
1-minute Apgar57 26 (2.8%) 2 (1.9%) 24 (3.0%) 0:42
5-minute Apgar57 2 (0.2%) 0 (0.0%) 2 (0.3%) 0:78
Data are given as frequencies (percent) or median (quartiles).
Table 3. Relationship between low PAPP-A levels (51st, 5th and 10th percentiles) and adverse pregnancy outcomes.
Outcome
10th
percentile
N¼ 103
10th
percentile
N¼ 813 p-Value
55th
percentile
N¼ 47
5th
percentile
N¼ 869 p-Value
51st
percentile
N¼ 10
1st
percentile
N¼ 916 p-Value
Preterm birth 1 (1%) 30 (3.7%) 0:24 0 (0%) 31 (3.6%) 0:40 0 (0%) 31 (3.4%) 1:0
GH 4 (3.9%) 17 (2.1%) 0:28 4 (8.5%) 17 (2.0%) 0:02 1 (10%) 20 (2.2%) 0:21
Preeclampsia 4 (3.9%) 8 (1%) 0:04 1 (2.1%) 11 (1.3%) 0:47 0 (0%) 12 (1.3%) 1:0
FGR 9 (8.7%) 18 (2.2%) 0:002 5 (10.6%) 22 (2.5%) 0:01 2 (20%) 25 (2.8%) 0:03
Low birth weight 8 (7.8%) 35 (4.3% ) 0:13 5 (10.6%) 38 (4.4%) 0:06 2 (20%) 41 (4.5%) 0:08
PPROM 0 (0%) 10 (1.2%) 0:61 0 (0%) 10 (1.2%) 1:0 0 (0%) 10 (1.1%) 1:0
Abruptio placentae 2 (1.9%) 1 (0.1%) 0:04 1 (2.1%) 2 (0.2%) 0:15 0 (0%) 3 (0.3%) 1:0
Gestational diabetes 15 (14.6%) 110 (13.5%) 0:77 6 (12.8%) 119 (13.7%) 1:0 3 (30%) 122 (13.5%) 0:15
Macrosomia 0 (0%) 3 (0.4%) 0:81 0 (0%) 3 (0.3%) 1:0 0 (0%) 3 (0.3%) 1:0
Oligohydramnios 1 (1%) 13 (1.6%) 1:0 0 (0%) 14 (1.6%) 1:0 0 (0%) 14 (1.5%) 1:0
FGR: fetal growth restriction; GH: gestational hypertension; PPROM: preterm premature rupture of membranes.
Figures in bold were statistically significant.
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This study suggests that an unexplained low level of PAPP-A (510th
percentile) during ﬁrst-trimester can be associated with adverse out-
comes, namely preeclampsia, fetal growth restriction and abruptio pla-
centae, as was suggested by previous studies. However, there was not
always an increased risk as the PAPP-A level became increasingly
extreme and probably the use of510th percentile threshold can be
more clinically useful. In this study, low levels of free b-hCG (51st,
5th and 10th percentiles) were not associated with adverse outcomes.
Other studies demonstrated an association between low levels of free b-
hCG (50.4 or 0.5 MoM) and birthweight below the 5th or 10th per-
centile (OR 1.6–1.7).4,6 If PAPP-A and free b-hCG reﬂect placentation
quality, low levels should be associated with deﬁcient placentation that
occurs in preeclampsia and fetal growth restriction. On the other hand,
PAPP-A is known to be an insulin-like growth factor-binding protein
protease and to increase the bioavailability of insulin-like growth
factor (IGF), that plays an important role in fetal growth18 by mediat-
ing trophoblast invasion, and to regulate steroidogenesis and glucose
and amino acid transport in the chorionic villi.19The mechanism
involved with most adverse outcomes such as preeclampsia and fetal
growth restriction may be related to the protease activity of PAPP-A
aﬀecting free IGF concentrations in early pregnancy, and probably this
marker is the best predictor for these outcomes. There was no relation-
ship between high PAPP-A or free b-hCG levels and adverse outcome.
These results are in agreement with previous publications.4,6,7,10,20 If
free b-hCG is increased when oxygen tension is low, as in preeclampsia
and fetal growth restriction, this could be a plausible theory to explain
adverse outcomes in these women. However, for the time being, there is
no known consistent association. Lastly, if impaired establishment of
utero-placental circulation during the ﬁrst trimester may inﬂuence the
physiological decrease of NT thickness in late ﬁrst trimester, increased
fetal NT measurement should be associated with adverse outcomes.
Tsai et al.21 conclude that the sensitivity of fetal NT measurement in
ﬁrst trimester is not suﬃcient as a single marker for predicting the risk
of preeclampsia. In this study this association has not been demon-
strated probably because NT is a late marker in ﬁrst trimester and this
work included women who underwent ﬁrst-trimester screening earlier.
Preeclampsia
Previous studies suggested low PAPP-A as a marker for subsequent
development of preeclampsia.4,6,13,22–24 In this work, the resulting
AOR for preeclampsia was signiﬁcantly higher than the results from
other studies, with a fourfold increased risk. Smith et al.4 examined the
relationship between PAPP-A 5th percentile and preeclampsia and
found a statistically signiﬁcant increased risk (OR 2.3). Dugoﬀ et al.6
found an increased risk of preeclampsia (OR 1.34) when PAPPA was
10th percentile. In the present study, the 10th percentile threshold was
the only one statistically signiﬁcant, probably given the small number
of cases in PAPPA level55th percentile group. PAPP-A510th per-
centile demonstrated low sensitivity and PPV, limiting its clinical
utility.
Fetal growth restriction
Low serum PAPP-A level may represent early onset placental dysfunc-
tion. In this study, the resulting AOR for fetal growth restriction was
higher than the results from other studies, with a threefold increase
risk. There was an increased risk of fetal growth restriction as the
PAPP-A level became increasingly extreme. Dugoﬀ et al.6 found an
increased risk of fetal growth restriction (OR 2.15) when PAPP-A was
510th percentile and maternal serum free b-hCG was mildly reduced in
pregnancies that subsequently developed fetal growth restriction.
Goetzinger et al.25 concluded that black race (OR 2.9), b-hCG MoM
490th percentile (OR 1.6), and PAPP-A MoM55th percentile (OR
2.8) were signiﬁcant predictors for fetal growth restriction. The asso-
ciation between low PAPP-A levels and fetal growth restriction has
been consensual in other studies, however the use of free b-hCG is
unsatisfactory until today.20,26 PAPP-A510th percentile demonstrated
low sensitivity and PPV. Smith et al.4 concluded that the sensitivity of
detecting fetal growth restriction for a ﬁrst trimester PAPP-A level
below the 5th percentile is low and PAPP-A as single marker is prob-
ably an insuﬃcient screening tool. The same group concluded later that
women with low levels of PAPP-A between 10 and 14 weeks and high
levels of AFP between 15 and 21 weeks, were more likely to deliver a
low birth weight infant, probably reﬂecting the combined eﬀect of two
independent pathophysiologic processes in early placental develop-
ment.27 In this study, for PAPP-A51st percentile (50.28 MoM) and
PAPP-A55th percentile (50.42 MoM) PPVs were 20% and 10,6%,
respectively, similar to the results of Krantz et al.7 However, the major-
ity of patients with these adverse outcomes do not have a PAPP-A
55th and these results should be carefully interpreted.
Abruptio placentae
Some authors have questioned if low PAPP-A may be a marker for
development of abruption placenta. In this study, the 10th percentile
threshold was the only one statistically signiﬁcant and the resulting OR
for abruptio placentae was very high, with a ﬁftyfold increase risk, but
with only with a low PPV (1.94). Until this study, no signiﬁcant
increase in relative risk has been noted for abruptio placentae.24,28
Low levels of PAPP-A in the ﬁrst-trimester have been associated
with abnormal placental morphometry. There is also an evidence link-
ing abnormal trophoblastic invasion of the decidua, thrombotic
changes in the spiral arteries and abruption-induced preterm births.29
Although the majority of studies were not focused on abruptio placen-
tae, low PAPP-A can be associated with this outcome. Blumenfeld
et al.30 suggested that ﬁrst-trimester PAPP-A55th percentile was asso-
ciated with placental abruption (AOR 1.9). In this study, due to the
small sample size, there were no possible conclusions, however this
association can be analysed in future studies.
No signiﬁcant increase in relative risk was noted for other adverse
outcomes evaluated including: preterm birth; low birth weight;
PPROM; gestational diabetes; macrosomia; and oligohydramnios.
Limitations
This study has several limitations. Outcome data were not available for
93 women, but the patients evaluated did not diﬀer signiﬁcantly from
those who were excluded. The median maternal age of this study popu-
lation was high. However, maternal age was not signiﬁcantly diﬀerent
between women with low versus high PAPP-A levels. Sample size was
insuﬃcient to analyze some rarer outcomes.
Table 4. Adverse outcomes associated with PAPP-A510th percentile (0:52 MoM).
Outcome AOR 95% CI p-Value Sensitivity Specificity PPV NPV
Preeclampsia 4:13 1.15–14.80 0:03 33:3 89:1 3:9 99:0
Fetal growth restriction 3:94 1.68–9.26 0:002 33:3 89:4 8:7 97:8
Abruptio placentae 52:63 1.41–100.0 0:03 66:7 88:9 1:9 99:9
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Conclusion
This study suggests that women with abnormal PAPP-A level, less than
10th percentile, could have a higher risk for preeclampsia, fetal growth
restriction and possibly for abruptio placentae. For fetal growth
restriction, the lower the MoM value of PAPP-A, the higher the
chances of an adverse outcome. However, the majority of patients
with these adverse outcomes do not have a low PAPP-A and, therefore,
the sensitivity is low. In addition, few patients with a low PAPP-A
actually have an adverse outcome (low PPV). There is no consensus
yet as to how these pregnancies should be managed. In the absence of
such evidence, no changes in clinical practice are indicated.12The
Society of Obstetricians and Gynecologists of Canada Genetics
Committee recommends that obstetricians should establish a care
plan that takes into account the speciﬁc risks of each patient, including
patient education, ultrasonography to assess fetal growth and amniotic
ﬂuid volume, cervical length, second trimester uterine artery Doppler
examination and fetal surveillance.12 Further investigation is needed to
determine whether if any type of monitoring and intervention protocol
would improve pregnancy outcome when abnormal markers are
detected.
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